Position statement as regards stem cell therapy generally
and some specific disease types.
Regenecell treatment protocol is based on a combination of information
acquired from years of treating patients, without the occurrence
of a single adverse event, and the continuous monitoring of treatment
methods utilised in FDA-approved clinical trials.
SCT (stem cell therapy) - of any kind - is not a cure for any
disease nor can any response be predicted. All responses quoted
by Regenecell are based on previous patient treatment responses.
Regenecell will not perform treatment on any patient unless this
is acknowledged. Stem cell therapy in general may improve symptoms
and could improve eventual disease outcome and life expectancy.
No patient has ever been cured of disease by means of SCT.
Responses in continuously degenerating disease:
These are dependent on the speed of degeneration e.g. in Multiple
Sclerosis responses are best in patients with slowly progressive
or static disease. Responses in ALS are few, due to the fact that
it is a very rapidly degenerating disease and patients present
late. Neuromuscular involvement in ALS is a bad sign, is permanent,
and has never been shown to reverse with stem cell therapy. In
these kinds of diseases we recommend that patients undergo SCT
only if the following criteria are met:
1. The disease state is life-threatening and the therapy could
increase quality of life, prolong life or treat the critical condition
to reduce the mortality potential.
2. Specific neurological deficit is disabling and has shown responses
in previous patients.
3. The patient, after showing a clear understanding of the limitations,
specifically requests it.
Diabetes
SCT has been shown to improve diabetic control for up to 3 years
and could improve outcome and life expectancy by treating the
cardiac, renal, ophthalmic and neurological complications of diabetes.
It will not cure diabetes and will not rejuvenate the pancreas
even if pancreatic stem cells are used.
Eye
disease
Intraocular disease has also shown responses, and those patients
are treated at our specialist unit in Bangkok.
SCI
Incomplete spinal cord injuries respond better than complete spinal
cord injuries, but we will treat both. No person with a spinal
cord injury has ever experienced total resolution of their injury
post-treatment.
Liver
and renal disease
These organs show good uptake of stem cells and the liver has
good regenerative potential even in Hepatitis B & C and cirrhosis.
SCT in late stage renal disease shows limited usefulness.
Autism
Initial responses appear positive, but insufficient data is available
and responses seem to be dependent on the age of the child.
Epilepsy
This does not seem to respond very well to SCT even if it is part
of a disease that does respond well to SCT.
Genetic diseases and inborn errors of metabolism
These have not shown good responses.
Arthritis
Immune mediated arthritis shows temporary response of up to 3
years. Arthritic joints have shown responses with intra-articular
injections of mesenchymal cells.
Best responses
The best responses have been found in cerebral
palsy in children under 12, brain injury, stroke
and cardiac
failure.
Should you have any questions, your Regenecell
counselor would be more than willing to assist.
